Aspen Prices Autologous Cell Therapy IPO
Aspen Neuroscience priced a US IPO on 29 October: 9,375,000 primary shares at $15, yielding about $140.6 million expected gross proceeds before fees. Trading under ASPE was scheduled for 30 October; the offer was…
